Beijing Shuanghe Runchuang Technology

Beijing Shuanghe Runchuang Technology is a wholly-owned subsidiary and the core innovative drug R&D platform of China Resources Double-Crane Pharmaceutical. Established in 2021, the company focuses on the discovery and development of first-in-class and best-in-class small molecule therapeutics targeting oncology, rare diseases, pediatrics, and autoimmune disorders. It operates an AI-driven innovative drug development and concept verification platform that integrates advanced artificial intelligence with extensive industrial resources to accelerate the translation of scientific discoveries. The company's clinical pipeline features DC05F01, a first-in-class Fascin protein inhibitor in Phase 1/2 trials for advanced solid tumors, and DC6001, a novel small molecule for Stargardt disease in Phase 1 trials. Shuanghe Runchuang is also advancing several other promising candidates, including the PRMT5 inhibitor DC50292A and the autoimmune program DC7001A.